NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 24.8% from a year ago
Cash & equivalents stood at $424.15M at the end of Q2 FY2026, down 24.8% from a year earlier and down 7.3% from the prior quarter. Over 3 fiscal years it compounded at +1.6% a year.
Context
- Cash & equivalents amounted to 60.2% of total assets at the end of Q2 FY2026, down 9.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -24.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 490M USD
- Year-over-year change
- -36.5%
- 4-year CAGR
- +68.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 490M | -36.5% |
| FY2024 | 2024-12-31 | 771.74M | +126.7% |
| FY2023 | 2023-12-31 | 340.45M | -27.2% |
| FY2022 | 2022-12-31 | 467.73M | +674.6% |
| FY2021 | 2021-12-31 | 60.38M | — |
Cash & Equivalents vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -24.8% is the 8th highest of 9, against a peer median of +50.0%.
- Cash & equivalents amounts to 60.2% of total assets for NAMS, versus a peer median of 28.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $424.15M USD | -24.8% | +1.6% | 60.2% | |
| Jun 2026 | $292.73M USD | +57.2% | -15.7% | 23.5% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M USD | -6.1% | +89.8% | 60.8% |
| Sep 2026 | $240.1M USD | +6.6% | +53.6% | 30.5% | |
| Jun 2026 | $201.53M USD | +42.7% | -2.0% | 17.4% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M USD | -47.8% | +58.0% | 27.0% |
| Jun 2026 | $125.75M USD | +271.2% | +65.4% | 24.1% | |
| Mar 2026 | $51.8M USD | +71.7% | -25.4% | 38.8% | |
| Dec 2025 | A$49.15M AUD | +983.5% | -1.6% | 86.4% | |
| Peer median (excluding NAMS) | — | +50.0% | +26.0% | 28.7% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.38M | 467.73M | 340.45M | 771.74M | 490M |
| Short-term Investments | 0 | 0 | 0 | 62.45M | 146.24M |
| Net Receivables | 5.51M | 0 | 1.88M | 21.31M | 23.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (627.81K) | 2.07M | 0 | 0 | 1.32M |
| Total Current Assets | 66.96M | 477.98M | 346.79M | 863.41M | 675.7M |
| Property, Plant & Equipment (Net) | 216.08K | 154K | 101K | 673K | 568K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 208K | 170K | 534K | 407K |
| Long-term Investments | 138.02M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (137.2M) | 156K | 35K | 0 | 92.61M |
| Total Non-current Assets | 1.03M | 518K | 306K | 1.21M | 93.58M |
| Total Assets | 67.99M | 478.5M | 347.1M | 864.62M | 769.28M |
| Account Payables | 7.07M | 11.85M | 16.92M | 4.74M | 8.97M |
| Short-term Debt | 0 | 0 | 0 | 0 | 136K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 8.94M | 6.01M | 3.99M |
| Other Current Liabilities | 0 | 18.02M | 15.96M | 91.03M | 72.69M |
| Total Current Liabilities | 11.24M | 36.06M | 49.9M | 106.92M | 85.79M |
| Long-term Debt | 0 | 0 | 0 | 0 | 66K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 1.02M | 0 | 0 |
| Other Non-current Liabilities | 0 | 12.31M | 7.79M | 0 | 0 |
| Total Non-current Liabilities | 126.24K | 12.37M | 8.81M | 202K | 66K |
| Total Liabilities | 11.36M | 48.43M | 58.7M | 107.12M | 85.85M |
| Common Stock | 128.51K | 10.06M | 10.17M | 13.44M | 14.28M |
| Retained Earnings | (39.44M) | (140.04M) | (316.97M) | (558.57M) | (762.39M) |
| Accumulated OCI | 672.13K | 4.42M | 4.42M | 4.47M | 4.79M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 56.63M | 430.07M | 288.39M | 757.5M | 683.43M |
| Total Debt | 186.51K | 126K | 60K | 448K | 202K |
| Net Debt | (60.19M) | (467.6M) | (340.39M) | (771.3M) | (489.8M) |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.